Department of Orthopedic Oncology, The Cancer Institute Hospital of The Japanese Foundation for Cancer Research, Tokyo, Japan
Department of Orthopedic Oncology, The Cancer Institute Hospital of The Japanese Foundation for Cancer Research, Tokyo, Japan.
Anticancer Res. 2020 Feb;40(2):1035-1039. doi: 10.21873/anticanres.14039.
Extraskeletal myxoid chondrosarcoma (EMC) is a rare malignant soft-tissue tumor and often shows extracompartmental tumoral invasion. The aim of our study was to investigate the clinical features, especially extracompartmental tumoral invasion (ETI) of EMC.
A total of 35 operative patients diagnosed with EMC were enrolled in this study from January 1980 to March 2018 in the Cancer Institute Hospital of The Japanese Foundation for Cancer Research. The operative procedure was principally wide excision. Univariate analysis assessed how clinicopathological factors (e.g. age, gender, tumor site, tumor size, histopathological grade, surgical margin, metastasis before operation, barrier invasion, local recurrence, metastasis after operation) influenced patient prognosis. We assessed how clinicopathological factors influenced ETI of EMC.
Among 35 patients, 10 patients showed ETI. The average follow-up was 5.57 (range=0.2-20 years). The 5- and 10-year overall survival was 91.3% and 71.2%, respectively. The 5- and 10-year overall survival of patients with M0 disease was 96.1% and 73.2%, respectively, while both were 75.0% for those with M1 disease, respectively. The patients with distant metastasis at first visit tended to have a poor prognosis (p=0.07). It is notable that all of the 10 patients with ETI had distant metastasis after surgery.
Patients with distant metastasis at first visit tended to have a poor prognosis. ETI of EMC induced distant metastasis after surgery. Patients with ETI of EMC should, therefore, be carefully monitored over a prolonged period.
骨外黏液样软骨肉瘤(EMC)是一种罕见的恶性软组织肿瘤,常表现为跨筋膜肿瘤侵袭。本研究旨在探讨 EMC 的临床特征,尤其是跨筋膜肿瘤侵袭(ETI)。
1980 年 1 月至 2018 年 3 月,日本癌症基金会癌症研究所共收治 35 例 EMC 手术患者。手术方法主要为广泛切除术。单因素分析评估了临床病理因素(如年龄、性别、肿瘤部位、肿瘤大小、组织病理学分级、手术切缘、术前转移、屏障侵犯、局部复发、术后转移)如何影响患者预后。我们评估了临床病理因素如何影响 EMC 的 ETI。
35 例患者中,10 例有 ETI。平均随访时间为 5.57 年(范围 0.2-20 年)。5 年和 10 年总生存率分别为 91.3%和 71.2%。M0 疾病患者的 5 年和 10 年总生存率分别为 96.1%和 73.2%,而 M1 疾病患者的 5 年和 10 年总生存率分别为 75.0%。首次就诊时有远处转移的患者预后较差(p=0.07)。值得注意的是,所有 10 例有 ETI 的患者术后均有远处转移。
首次就诊时有远处转移的患者预后较差。EMC 的 ETI 导致术后远处转移。因此,EMC 有 ETI 的患者应长期密切监测。